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Background. Culture-negative periprosthetic joint infections (CN PJI) have not been well studied, and due to the lack of consensus
on PJI, especially with culture-negative infections, there are considerable uncertainties. Due to the challenging clinical issue of CN
PJI the aim of this systematic review is to describe incidence, diagnosis, and treatment outcomes based on the current literature on
CN PJI. Hypothesis.The review is designed to assess the formal hypothesis that CN PJI of the hip and knee have a poorer outcome
when compared with culture-positive ones. Study Design. It is systematic review with level of evidence 3. Methods. EMBASE,
MEDLINE, and the Cochrane Library were searched electronically in January 2018. All studies regarding CN PJI of the hip or knee
published in English or German with a minimum of 10 patients were included. Afterwards, the authors performed a descriptive
analysis of diagnosis and treatment outcome. Result. Eight studies were identified that met the inclusion criteria. The incidence of
CN PJI in the hip or knee ranged from 7% to 42 %. The included studies were pooled to give an overall incidence rate estimate
of 11 % [95% confidence interval (CI): 10-12] based on a random-effects model. The most common surgical intervention was the
two-stage revision of prosthesis with 283 patients. Postoperatively, the majority of patients received vancomycin as the antibiotic
treatment, alone or in combination with other antibiotics. The rate of succesfully treated infections varied from 85% to 95 % in all
included studies. The two-stage exchange arthroplasty had the best outcome, based on the infection-free survival rate of 95%, five
years after treatment. Conclusions.We conclude that CN PJI have the same or even better results than culture-positive infections.
Nonetheless, a standardized diagnostic protocol and evidence-based treatment strategies for CN PJI should be implemented for
further studies.
1. Introduction
When performing arthroplasty of the hip or knee, peripros-
thetic joint infections are among the most serious com-
plications after the procedure. 1% of all hip replacements
and 2-3% of primary knee prostheses are affected [1, 2]. In
the future, a rise in infections is likely due to an increase
of implantations, increasing lifespans of patients and the
resultant longer prostheses retention times.
Due to a lack of consensus on diagnosis and treatment
of periprosthetic joint infections, especially culture-negative
infections, there still seem to be considerable uncertainites.
Different diagnostic protocols for detecting periprosthetic
joint infections have been published, and hence there seems
to be no standardized protocol being used across studies [3–
13].
Moreover, comparisons of treatment outcomes are diffi-
cult to make, as the current evidence does not conclusively
support a superior treatment strategy for periprosthetic joint
infections.
The culture-negative periprosthetic joint infection is even
more demanding in diagnosis and treatment, as without
positive culture the uncertainty about the correct diagnosis
of infection grows. Without knowing the causing microor-
ganism, it is a challenge to determine the right treatment
and choice of antibiotics for any patient. This is all the more
difficult due to the sparse existing literature on the treatment
and outcome of CN PJI.
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Table 1: Search strategy.
Search # Query
#1 periprosthetic infection or periprosthetic joint infection or surgical wound infection or prosthesis-related infection
#2 knee arthroplasty or total knee arthroplasty or knee replacement or knee prosthesis or arthroplasty, replacement, knee
#3 hip arthroplasty or total hip arthroplasty or hip replacement or hip prosthesis or arthroplasty, replacement, hip
#4 Culture negative OR culture
#6 #1 AND #2 AND #4
#7 #1 AND #3 AND #4
This systematic review therefore aims to give an overview
on the current database of studies concerning culture-
negative periprosthetic joint infections of the hip and knee.
The different diagnosis protocols and results after treatment
were analyzed, and whether culture-negative infections really
have a worse outcome when compared to culture-positive
ones was evaluated.
2. Material and Methods
In January 2018 the authors conducted a systematic liter-
ature search of MEDLINE, EMBASE via OvidSP, and the
Cochrane Library addressing culture-negative periprosthetic
joint infections. To identify additional studies that possibly
fit the criteria and had not been discovered via the electronic
database search, the authors reviewed the bibliographies of
the chosen studies and review articles. The systematic review
has been reported in accordance with the PRISMA statement
[14]. See Table 1 for search terms used.
Inclusion criteria comprised studies published in English
or German, numbers of patients >10, and studies regarding
culture-negative periprosthetic joint infections after arthro-
plasty of the knee or hip. Although two-stage exchange
arthroplasty is the most widely performed procedure, all
treatment strategies were included in the search. Studies with
prosthetic joint infections of another region than knee or
hip were excluded, as well as case reports, review articles,
opinion of experts, and letters to the editors. The abstracts
of the selected studies were screened. If they were found
to be inadequate, the full text was evaluated to determine
whether a study was eligible for inclusion. Two of the
authors independently carried out the process described
above. Lack of consensus was resolved by thorough discus-
sion. A level of evidence based on The Journal of Bone
and Joint Surgery guidelines was then assigned to every
article. Different variables for a comparative analysis of
the outcome of each study were included in a data sheet
(Table 2). A descriptive review of the variables, such as the
infection control rate and outcome of the included studies,
was drafted, and a comparison between all studies was per-
formed. The included studies were pooled to give an overall
incidence rate based on a random-effects model with 95%
confidence interval (CI). Heterogeneity between the studies
was assessed with a chi-square-test and quantified with I2
statistics. Publication bias was evaluated with funnel plot
analysis.
3. Results
A flow chart of our literature research was created using the
PRISMA (Preferred Reporting Items for Systematic Reviews
and Meta-Analyses) guidelines (Figure 1).
532 potential studies matching our inclusion criteria were
identified via the search strategy andmanual screening of the
bibliographies of relevant studies. We excluded 477 studies
after reviewing title and abstract. This left 49 full-text studies
to be assessed for eligibility. Finally, 8 papers were selected for
inclusion in our systematic review andmeta-analysis [15–22].
Table 2 shows short summaries of the results of all
included studies. All studies have retrospective character
and lower quality, with level III of evidence based on The
Journal of Bone and Joint Surgery guidelines. All studies
were published between 2007 and 2017. The incidence rate of
culture-negative periprosthetic infections in the hip or knee
ranged from 7% to 42 % with a total number of all included
patients being 3,342. Of these, 504 were culture-negative
(Figure 2).The included studies were pooled to give an overall
incidence rate estimate of 11 % [95% confidence interval (CI):
10-12] based on a random-effects model (Figure 3).
Funnel plot analysis of included studies assessing the
overall incidence of CN PJI revealed a publication bias
(Figure 4). 36% of all included culture-negative cases were
periprosthetic hip infections, and 64% were prosthetic knee
infections. A total number of 137 patients were treated for
irrigation and debridement with retention of the prosthesis,
16 patients with one-stage exchange arthroplasty, 42 with
permanent resection of the joint, and 26 patients with other
treatment options like chronic antibiotic suppression. The
two-stage revision of prosthesis was the most common
surgical intervention with a total number of 283 patients.
The studies differ in the diagnostic protocols used to identify
culture-negative infections. Often the diagnostic criteria of
the Musculoskeletal Infection Society [8] are used as a
reference. To better compare the included studies, a graphic
was created (Figure 5).
As a postoperative antibiotic, vancomycin was used to
treat most of the patients in the included studies, either alone
or in combination with other antibiotics. In the studies of
Berbari et al. andMalekzadeh et al. cephalosporinsweremore
commonly used to eliminate a periprosthetic joint infection.
The relevant studies documented prior use of antibiotics as a
risk factor for culture-negative periprosthetic infections.
The included studies define a successful treatment with
variable parameters [15–22]. Intersections of the parameters
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Figure 1: Flow chart.
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Figure 2: Range of incidence of CN PJI.
are illustrated in the following graphic, excluding Li et al. as
the study did not specify parameters (Figure 6).
The rate of successful treated infections varied from 85%
to 95 % in all included studies. The majority of studies
observe infection-free survival rates in 3-year and 5-year
time-intervals.The overall infection-free survival rate ranged
from 67% to 94%. The two-stage exchange arthroplasty has
the best outcome with regard to the infection-free survival
rate with rates up to 95% five years after treatment. When
comparing the outcomes of culture-negative periprosthetic
infections with those of culture-positive periprosthetic infec-
tions, all studies came to the conclusion that culture-negative
infections have the same or, in the study of Choi et al., even
better results than culture-positives.
4. Discussion
Periprosthetic joint infections are serious complications that
may occur after joint replacement.The incidence ranges from
2% to 3% in primary knee [1, 2] and 1% to 4% in primary hip
replacement [2, 24]. In this systematic review, the incidence
rate of CN PJI ranged from 7% to 42% [15–22] with a pooled
incidence rate of 11%.
The aim of this study is to identify the relevant studies on
culture-negative periprosthetic joint infections from the hip
and knee and to analyze the reported incidences, diagnostic
protocols, and treatment outcomes.
Treating a periprosthetic infection even when the causing
organism is known is challenging in itself and a topic
of the current investigations [25–29]. When there is no
identification of the causing pathogen it is certainly an
even bigger challenge. A culture-negative infection is still
6 BioMed Research International






























Figure 3: Rates of incidence for culture-negative periprosthetic joint infections of the hip and the knee. Summary estimates for the incidence
of CN PJI were calculated using random-effects models with 95% confidence interval (CI). An I2 value (statistical heterogeneity) of 0.00%






























































Figure 4: Funnel plot analyses.
a subject of controversy because of a lack of literature
for a consistent diagnostic protocol and optimal treatment
recommendations. Because there are no consistent diagnostic
parameters, a comparison between the studies is complicated.
While reviewing the literature, the authors found different
classifications for the diagnosis of a periprosthetic joint
infection (Table 3).
A consistent usage from one classification, separated
from the author, joint, or location of the study was not
recognizable. Renz and Trampuz et al. published a diagnostic
protocol following the international recommendations for
usage in further studies tomake comparisons between studies
and results more reliable (Table 4). In the case that the
pathogen cannot be identified, there are three additional
parameters to confirm the periprosthetic joint infection.
Reasons for culture-negative periprosthetic joint infec-
tions are not definitely resolved.They could include inappro-
priate diagnostic tools for rare organisms such as mycobac-
terium, fungi, and others like Brucella or Coxiella burnetti
that are difficult to identify using routinemethods [15, 16, 30].
The most common risk factor in our systematic review for
culture-negative infection was the prior use of antibiotics
[15, 18, 22] which can compromise the sensitivity of routinely
used diagnostic laboratory tests. For this reason, Della Valle
et al. in the clinical practice guideline of American Academy
of Orthopedic Surgeons recommends that the antimicrobial
treatment be interrupted at least two weeks before aspiration
[5]. To increase the detection rate of the low-virulence
microorganisms multiple samples (minimum 3) should be
taken, and an adequate growth time of at least 14 days [2, 31]
should be allowed. Emphasis is placed on new diagnostic
tools for improving the sensitivity and specifying for diag-
nosis of culture-negative prosthetic joint infections, while
reducing the number of false-negative results. Trampuz et al.
demonstrated the importance of sonication of prostheses in
improving diagnosis of periprosthetic joint infections of the
knee and the hip, since this method attains more sensitivity
than conventional periprosthetic-tissue culture, particularly
in patients with prior antibiotic treatment [31]. The most
common molecular biological technique is the polymerase
chain reaction to detect the causing microorganism [32,
33]. Even unusual species like fungal periprosthetic joint
infections could be detected with a selective medium and an
increased incubation time [34]. The analyses of the synovial
fluid with new biomarkers are currently validated in clinical
studies [2]. The alpha-defensin test shows especially good
results in detecting a periprosthetic joint infection [2, 35, 36],
but it is yet to be validated in larger studies. Next-generation
sequencing has recently gained attention and is a topic of
current investigations to evaluate the accuracy in identifying
causing microorganisms in periprosthetic joint infections,
especially in culture-negative infections [37].
The outcome of PJI is determined by the choice of surgical
treatment. There are different treatment strategies, including
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Figure 5: Definition of diagnosis of culture-negative periprosthetic joint infections.
Figure 6: Definition of successful treatment.
irrigation, debridement, and retention of the prosthesis,
one-stage exchange arthroplasty, or two-stage exchange of
the prosthesis. The choice of the optimal treatment must
be made jointly by orthopedic surgeons and experienced
infectologists in accordance with the type of infection and
patient’s condition.
The largest amount of data in the literature is focused on
the two-stage exchange arthroplasty, since this is still con-
sidered the gold standard with the lowest reinfection rates,
from 0% to 36% [29, 38–44], and best functional outcomes
[45–49]. But studies researching the one-stage exchange
arthroplasty have also found similar reinfection rates, from
2% to 40% [27, 42, 45, 50–54]. In our systematic review most
patients with culture-negative periprosthetic joint infections
were treated with two-stage exchange arthroplasty, followed
by 4-6 weeks of antibiotic treatment.The two-stage exchange
has the highest infection-free survival rate up to 95% after five
years of follow-up and a success rate ranging from 70% up to
100%. Of the included studies none recommended one-stage
exchange as the first treatment option.
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Table 4: Diagnostic parameters for CN PJI [23].
Test Criteria Sensitivity Specificity
Clinical features Sinus tract (fistula) or purulence aroundprosthesisa 20-30% 100%
Leukocyte count in synovial fluidb >2000/ul leucocytes or >70%granulocytes (PMN) ≈90% ≈95%
Periprosthetic tissue histologyc Inflammation (≥23 granulocytes per 10high-power fields) 73% 95%
Microbiology
Microbial growth in:
(i) synovial fluid or
(ii) ≥2 tissue samplesd or







aMetal-on-metal bearing components can simulate pus (≪pseudopus≫), leukocyte count is usually normal (visible is metal debris)
bLeukocyte count can be high without infection in the first 6 weeks after surgery, in rheumatic joint disease (including crystalopathy), periprosthetic fracture
or luxation.
Leukocyte count should be determined within 24 h after aspiration bymicroscopy or automated counter; clotted specimens are treated with 10𝜇l hyaluronidase
cClassification after Krenn and Morawietz: PJI corresponds to type 2 or type 3
dFor highly virulent organisms (e.g. S. aureus, streptococci, E. coli) or patients under antibiotics, already one positive sample confirms infection
eUnder antibiotics, for S. aureus and anaerobes, <50 CFU/ml can be significant
Table 5: Antimicrobial treatment in CN PJI [23].
Microorganism Antibiotica Doseb Route
(red: difficult-to-treat) (check pathogen susceptibility before) (italic font: renal adjustment needed)
Culture-negative
Ampicillin/sulbactamc 3 × 3 g i.v.
for 2 weeks, followed by:
Rifampind + Levofloxacin 2 × 450 mg p.o.
2 × 500 mg p.o.
aTotal duration of therapy: 12 weeks, usually 2 weeks intravenously, followed by oral route.
bLaboratory testing 2x weekly: leukocytes, CRP, creatinine/eGFR, liver enzymes (AST/SGOT and ALT/SGPT). Dose-adjustment according to renal function
and body weight (<40/> 100kg).
cPenicillin allergy of NON-type 1 (e.g., skin rash): cefazolin (3 × 2 g i.v.). In case of anaphylaxis (= type 1 allergy such as Quincke’s edema, bronchospasm, and
anaphylactic shock) or cephalosporin allergy, vancomycin (2 × 1 g i.v.) or daptomycin (1 × 8 mg/kg i.v.).
Ampicillin/sulbactam is equivalent to amoxicillin/clavulanic acid (3 × 2.2 g i.v.).
dRifampin is administered only after the new prosthesis is implanted. Add it already to intravenous treatment as soon as wounds are dry and drains removed;
in patients aged >75 years, rifampin is reduced to 2 × 300 mg p.o.
The included studies used different parameters to define
a successful treatment. To evaluate and compare the outcome
after treatment, a consistent definition of a successful treat-
ment should be determined to enable a reliable comparison
between different studies and treatment options.
As was the case regarding the surgical treatment of PJI,
there is no consensus in the literature about a standardized
protocol for antibiotic usage, especially not in CN PJI.
Vancomycin was the antibiotic used to treat most of the
patients in our included studies after surgery, either alone or
in combination with other antibiotics. Choi et al. reported
that high-dosage vancomycin has a better outcome inCNPJI.
The rising usage of vancomycin in culture-negative infections
may also be encouraged by an increasing number of MRSA
infections [13]. Besides the antibiotic agent, the duration of
parental and oral antibiotic treatment is another uncertain
topic in the published literature, and no treatment protocol
has yet been established. Trampuz et al. therefore developed
a antimicrobial treatment based on international references
[23] (Table 5).
Our systematic review has several limitations. First of
all, the included studies are based on level III evidence and
retrospective in design, which leads to a limited validity of
the results of our study. Secondly, only studies published
in English or German were selected, resulting in a selective
presentation of included studies and results. Only eight
studies that met all inclusion criteria were assessed. This
led to a small sample size of patients, resulting in restricted
validity of our findings. Furthermore, this only allowed us to
perform a descriptive analysis of the data. Due to the small
sample size, statistical methods used in the meta-analysis
to summarize the results are statistically insignificant. With
a low heterogeneity in the incidence rates provided by
the studies we included, referral bias possibly affects the
results. The possibility of not having retrieved all relevant
information published on CN PJI should also be considered
as one of the limitations of our study. Further, due to the
lack of literature which deals with CN PJI and because of
publications focusing only on positive results treating CN
PJI, a publication bias is likely. Additionally, the included
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studies did not utilize a standardized treatment protocol
(e.g., different surgeons and operative standards, interval
between stages, spacer, antibiotic treatment, and duration),
which made a direct comparison of their results difficult.The
descriptive analysis could not address the functional status
after treatment in the selected studies because of missing
information in the primary studies.
When the microorganism is confirmed, treatment out-
comes are well documented in the literature. However,
treatment outcome of culture-negative PJI is only reported in
a few studies. In all eight studies included in this systematic
review, the clinical outcome and infection control rates are
similar to CP PJI groups or have even higher rates of
successful treatments [16]. At the same time, when assessing
the treatment success of CN PJI, one should consider the
relatively short follow-up of the included studies.
Also one of the recently published articles comparing
the outcome of culture-negative to culture-positive peripros-
thetic joint infections Kang et al. came to the conclusion that
CN PJI can be treated successfully and can even show a better
outcome regarding clinical course [55].
In conclusion, a culture-negative status may not be
a negative prognostic factor for treatment outcome. One
clearly significant factor is the appropriate selection of the
surgical and antimicrobial treatment according to the type
of infection, including additional factors like comorbidities,
status of the patient, and operative risk for the patient. To
increase the validity of the conclusions in further studies,
prospectively designed studies of culture-negative PJI should
implement a standardized diagnostic protocol and evidence-
based treatment strategies for culture-negative periprosthetic
joint infections. This will significantly increase the commen-
surability and thus yield more tangible recommendations.
Appendix
See Table 1 and Figure 4.
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